Lung Cancer | Physician's Weekly
Advertisement

Lung Cancer

Automated robust SBPT planning using EUD-based prediction of SBRT plan for patients with lung cancer.

Aug 16, 2021

To evaluate the quality of robust stereotactic body proton therapy (RSBPT) plans generated by one-clicking scripting method for patients with lung cancer.Retrospective analysis was performed on fifty ...

Automatic segmentation of lung tumors on CT images based on a 2D & 3D hybrid convolutional neural network.

Aug 05, 2021

A stable and accurate automatic tumor delineation method has been developed to facilitate the intelligent design of lung cancer radiotherapy process. The purpose of this paper is to introduce an autom...

Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review.

Jul 29, 2021

Patients with Eastern Cooperative Oncology Group Performance Status 2 (ECOG PS 2) are not included in most randomized clinical trials and registry studies. Nevertheless, immune checkpoint inhibitors a...

Preoperative 18F-FDG SUVmax >6.3 or Size >2.3 cm of primary lesions predict lymph nodes metastasis with higher negative predictive value in peripheral cT1 non-small-cell lung cancer.

Jul 22, 2021

Sublobar resection is suitable for peripheral cT1N0M0 non-small-cell lung cancer (NSCLC). The traditional PET-CT criterion (lymph node size ≥1.0 cm or SUVmax ≥2.5) for predicting lymph nodes metas...

Oxoplatin-B, a cisplatin-based platinum(IV) complex with photoactive BODIPY for mitochondria specific "chemo-PDT" activity.

Jul 12, 2021

Oxoplatin-B, a platinum(IV) complex [Pt(NH)Cl(L)(OH)] (1) of 4-methylbenzoic acid (HL) functionalized with 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) was prepared, characterized and its antit...

Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer.

Jun 24, 2021

Thoracic radiotherapy is complicated by acute radiation-induced adverse events such as radiation pneumonitis (RP) and radiation esophagitis (RE). Based on preclinical work and a randomized pilot tria...

Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage.

Jun 03, 2021

Torque teno virus (TTV) is a ubiquitous non-pathogenic virus, which is suppressed in immunological healthy individuals but replicates in immune compromised patients. Thus, TTV load is a suitable bioma...

Identification of CXCL13/CXCR5 axis's crucial and complex effect in human lung adenocarcinoma.

Mar 08, 2021

Immune escape and low response to immunotherapy are crucial challenges in present lung cancer treatment. In this study, we constructed a new immune-related classifier based on CXCL13/CXCR5, an importa...

Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer.

Feb 15, 2021

This study aimed to investigate the trend of cardiovascular disease (CVD)-specific mortality in patients with non-small cell lung cancer (NSCLC) and identify prognostic factors for CVD-specific death ...

Lung Cancer Screening with Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.

Feb 15, 2021

Patients with a prior history of cancer (PHC) are at increased risk of second primary malignancy, of which lung cancer is the most common. We compared the performance metrics of positive screening rat...

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.

Feb 15, 2021

This study aimed to evaluate the impact of KRAS status on the efficacy of first-line immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC).Patients with advan...

Secretome of Activated Fibroblasts Induced by Exosomes for the Discovery of Biomarkers in Non-Small Cell Lung Cancer.

Dec 31, 2020

Molecules involved in crosstalk between tumor cells and fibroblasts play vital roles in tumor progression. Extracellular matrix proteins, whose abundance is altered after being affected by tumor-deriv...

Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.

Dec 31, 2020

Tumor necrosis factor (TNF) and its receptors are widely expressed in non-small cell lung cancer (NSCLC). TNF has an established role in inflammation and also plays a key role in inflammation-induced ...

Alectinib vs. Crizotinib for ALK-Positive Non-Small-Cell Lung Cancer

Sep 18, 2020

Approximately 5% of all non-small-cell lung cancers (NSCLC) are anaplastic lymphoma kinase-positive (ALK-positive). This study aims to compare the safety and efficacy of alectinib with crizotinib as t...

Nintedanib with Pemetrexed and Cisplatin for Pleural Mesothelioma

Sep 18, 2020

Malignant pleural mesothelioma (MPM) is a cancer of the lining of the lungs, characterized by chest pain, shortness of breath, and dry cough. Nintedanib is a medication that targets various receptors ...

Nazartinib for Non-Small-Cell Lung Carcinoma

Sep 18, 2020

Non-small-cell lung carcinoma (NSCLC) is one of the most common types of lung cancers. The use of tyrosine kinase inhibitors (TKIs) is impeded by the emergence of the Thr790Met mutation in a majority ...

CME - Conference Highlights: AATS 2020

Sep 01, 2020

This course discusses the key findings of five studies presented at the 2020 virtual Annual Meeting of the American Association for Thoracic Surgery....

Angiotensin-Converting Enzyme Inhibitors and Risk of Lung Cancer

Aug 18, 2020

Angiotensin-converting enzyme (ACE) inhibitors help lower your blood pressure by relaxing your veins and arteries. Recent evidence suggests that the use of ACE inhibitors may increase the risk of lung...

Study Connects the Dots Between Smoking and Stroke Risk in African Americans

Jun 12, 2020

Risk increases as more cigarettes are smoked According to the Office of Minority Health of the Health and Human Services Administration, African Americans are 50% more likely to have a stroke than th...

ASCO: Gastric Cancer Patients Respond to Trastuzumab Deruxtecan

Jun 02, 2020

Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxte...